Nyxoah (NYXH) said Friday it commercially launched its Genio therapy for obstructive sleep apnea in England.
The company said it completed its first two Genio implants at University College London Hospitals.
Genio is now covered under the specialized services devices program of England's National Health Service, Nyxoah said.
The Genio system is Nyxoah's proprietary device implanted under the chin to help with sleep apnea symptoms.
Shares of the company were up more than 8% in recent Friday premarket activity.
Price: 8.57, Change: +0.69, Percent Change: +8.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.